Srs Capital Advisors, Inc. Celldex Therapeutics, Inc. Transaction History
Srs Capital Advisors, Inc.
- $977 Million
- Q2 2024
A detailed history of Srs Capital Advisors, Inc. transactions in Celldex Therapeutics, Inc. stock. As of the latest transaction made, Srs Capital Advisors, Inc. holds 139 shares of CLDX stock, worth $4,503. This represents 0.0% of its overall portfolio holdings.
Number of Shares
139Holding current value
$4,503% of portfolio
0.0%Shares
1 transactions
Others Institutions Holding CLDX
# of Institutions
195Shares Held
63.4MCall Options Held
206KPut Options Held
176K-
Wellington Management Group LLP Boston, MA8.08MShares$262 Million0.05% of portfolio
-
Black Rock Inc. New York, NY4.69MShares$152 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA3.74MShares$121 Million0.0% of portfolio
-
Kynam Capital Management, LP Princeton, NJ3.39MShares$110 Million9.76% of portfolio
-
Eventide Asset Management, LLC Boston, MA3.33MShares$108 Million2.17% of portfolio
About Celldex Therapeutics, Inc.
- Ticker CLDX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 46,772,400
- Market Cap $1.52B
- Description
- Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory diseases and various forms of cancer. The company's clinical development programs CDX-01...